Company Snapshot
- Ticker
- VTRS
- Name
- VTRS
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 13579236000.000000
- Volume
- 7,343,577
- Avg Volume (3M)
- 9,193,416
VTRS
VTRS
Last update recent
11.66
+0.01
(+0.09%)
Market Cap
13579236000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 14124400000.000000
- EPS
- -3.09
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 4.17%
- Net Income
- -3691299999.000000
- Net Margin
- -26.13%
- Payout Ratio
- -15.34%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- -3.68
- Forward P/E
- None
- P/S
- 0.96
- P/B
- 0.89
- Beta
- None
- Debt / Equity
- 0.97
- Current Ratio
- 1.26
- Return on Equity
- -0.24%
- Return on Assets
- -0.10%
Technicals & Returns
- Distance vs 200 DMA
- 25.43%
- 200 DMA
- 9.30
- Distance vs 50 DMA
- 11.48%
- 50 DMA
- 10.46
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, Read more
- Name
- VTRS
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Scott Andrew Smith
- Employees
- 33,000
- IPO Date
- 1980-03-17
- Phone
- 724 514 1800
- Address
- None
- Website
- https://www.viatris.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-08-23 • $0.12
Latest News
Curated headlines from premium sources.
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete R…
Mark Cuban Takes Aim at FDA Fees
Viatris (VTRS) and Teva Pharma (TEVA) could soon face fresh competition after billionaire entrepreneur Mark Cuban called on Washington to scrap a fee he says is
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
Management to Participate in 8th Annual Evercore Annual Healthcare Conference Management to Participate in 8th Annual Evercore Annual Healthcare Conference
Viatris to Participate in Upcoming Investor Conferences
PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two u…